Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq

Renal Insufficiency, Chronic Clinical Trial

— OPTIMA  

Official title:

Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00234533
• Other study ID #: 2-79-58035-700
• Secondary ID: 2004-000356-17
• Status: Completed
• Phase: Phase 3
• Start date: June 2004
• Est. completion date: July 2008

Study information

• Verified date: November 2019
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 251
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Children under 18 with growth failure associated with inadequate growth hormone secretion, or Turner syndrome or chronic renal insufficiency.

Exclusion Criteria:

• Children with closed epiphyses

• Children with active neoplasm

• Children with acute critical illness

Related Conditions & MeSH terms

• Dwarfism
• Gonadal Dysgenesis
• Pituitary Diseases
• Primary Ovarian Insufficiency
• Renal Insufficiency
• Renal Insufficiency, Chronic
• Turner Syndrome

Intervention

Drug:
• Somatropin (rDNA origin)
Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.

Locations

Country	Name	City	State
Belgium	Dienst Kindergeneeskunde	Brussels
Belgium	Dienst Kindergeneeskunde	Edegem
Czechia	Klinika Deti a Dorostu	Praha
Denmark	Aalborg Sygehus Nord, Borneafdelingen	Aalborg
Denmark	Sygeh. i Ringkjobing Amt, Borneafdeling	Herning
Finland	Helsinki University Central Hospital	Helsinki
France	CHU - Hôtel Dieu	Angers
France	Cabinet Médical	Bordeaux
France	CHU Grenoble	Grenoble
France	Centre Hospitalier General	Le Havre
France	CHU Timone Enfants	Marseille
France	CHU de Montpellier	Montpellier
France	Hôpital Archet 2	Nice
France	Groupe Hospitalier de Necker	Paris
France	Hôpital Saint-Vincent de Paul	Paris
France	Hôpital Charles Nicolle	Rouen
France	CHU Hautepierre	Strasbourg
France	Centre Hospitalier de Bigorre	Tarbes
France	Cabinet Médical	Toulouse
France	Hôpital des Enfants	Toulouse
France	Centre Pédiatrique Gatien de Clocheville	Tours
Germany	Universitätsklinikum Leipzig AöR	Leipzig
Germany	Universitätsklinikum Tübingen	Tübingen
Greece	General State Hospital of Nikaia	Athens
Greece	PA Kyriakou Children's Hospital	Athens
Italy	Azienda Policlinico - Università di Catania	Catania
Italy	Ospedale Policlinico	Chieti
Italy	Clinica Pediatrica II	Firenze
Italy	Clinica Pediatrica, Universita Federico II di Napoli	Napoli
Italy	Il Università degli Studi di Napoli	Napoli
Italy	Clinica Pediatrica	Novara
Italy	Clinica Pediatrica	Parma
Romania	Institutul de Endocrinologie C.I. Parhon	Bucuresti
Russian Federation	Endocrinology Research Centre RAMS, Institute of Pediatric Endocrinology	Moscow
Russian Federation	Tushino Pediatric Hospital, RMAPE Department of Endocrinology for Childhood and Adolescent Age	Moscow
Slovakia	Il Detska Klinika	Bratislava
Spain	Hospital de Nens de Barcelona	Barcelona
Spain	Hospital General Universitario	Elche
Spain	Hospital Gregorio Marañón	Madrid
Spain	Hospital Parc Taulí	Sabadell
Spain	Hospital Clínico Universitario	Santiago de Compostela
Ukraine	Scientific-Research Institute of Endocrinology, Academy of Medical Science of Ukraine	Kiev
Ukraine	Ukrainian Scientific practical Centre of Endocrine surgery, Endocrine Organs and Tissues Transplantation	Kiev
United Kingdom	University Hospital Wales	Cardiff	Wales
United Kingdom	St George's Hospital	London	England

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Countries where clinical trial is conducted

Belgium,  Czechia,  Denmark,  Finland,  France,  Germany,  Greece,  Italy,  Romania,  Russian Federation,  Slovakia,  Spain,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples	Fingertip capillary blood was collected using filter paper cards for the assay of capillary blood spot IGF-I in line with the monitoring recommendations of the Lawson Wilkins Paediatric Endocrine Society (LWPES) for treatment with recombinant GH therapy in children.; Capillary IGF-I assays were performed by the patient at home one day per week during Weeks 21, 22 and 23 only (same week day). The samples were scheduled in the evening prior to the injection of NutropinAq and between 7:00 and 9:00 the following morning. An extended window from 6:00 to 12:00 was allowed for defining protocol deviations.; The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients was assessed. IGF-I measurements for the morning and evening sampling are presented.	At Weeks 21, 22 and 23
Secondary	Assessment of IGF-I Levels: Categorised by Weekly Timing (Weeks 21-23) and Daily Timing (Morning and Evening)	The influence of daily and weekly timing on the IGF-I value as measured using the capillary blood spot method was analysed. A 3-way analyses of variance (ANOVA) was performed with patient, day and daily timing as factors after appropriate transformation to obtain normally distributed parameters. The interaction day*time was tested and kept in the model only if p-value<0.1. Parameter estimates from the statistical model are presented as least squares means for the categories of daily timing (Morning and Evening) and weekly timing (Week 21, Week 22 and Week 23). The values reported for Week 21, 22, and 23 represent the average IGF-I levels from the morning and evening samples at each week. The values reported for Evening represent the Evening IGF-I levels averaged across Weeks 21, 22, and 23, and similarly for the Morning values.	At Weeks 21, 22 and 23
Secondary	Assessment of IGF-I Levels: Categorised by Sex and Prepubertal Status	The influence of sex and prepubertal status on the IGF-I value as measured using the capillary blood spot method was analysed. Parameter estimates from the statistical model are presented as least squares means for the categories of sex (male and female) and prepubertal status (pubertal and prepubertal). The values reported represent average IGF-I levels as determined from the 6 measurements taken (i.e. morning and evening samples at Weeks 21, 22 and 23).	At Weeks 21, 22 and 23
Secondary	Multivariate Linear Regression Analyses to Assess Factors Affecting the Variability of IGF-I Levels: Categorised by Disease Condition and Location	A multivariate linear regression analysis of factors on within-subject coefficient of variation (WCV) using a stepwise forward-backward elimination was used to determine the effect of individual factors on IGF-I values as measured using the capillary blood spot method (p=0.15 for a variable to enter and remain in the model). The WCV was computed from the series of 6 measurements (2 samplings in each of Weeks 21, 22 and 23). The influence of disease condition and country clusters on the IGF-I value were assessed.; Country clusters: cluster 1: France; cluster 2: Spain, Greece, Romania and Italy; cluster 3: UK, Belgium, Czech Republic, Denmark, Germany, Slovakia, Austria and Finland ; cluster 4: Russia ; cluster 5: Ukraine.; Parameter estimates from the statistical model presented as least squares means for categories of disease condition (GHD and TS) and location (Clusters 1, 2, 3, 4 and 5) are presented.	Up to Week 24
Secondary	Multivariate Linear Regression Analyses to Assess Factors Affecting the Variability of IGF-I Levels: Categorised by Time of Year, Calculated Age at Enrolment and Disease Condition	A multivariate linear regression analysis of factors on WCV using a stepwise forward-backward elimination was used to determine the effect of individual factors on IGF-I values as measured using the capillary blood spot method (p=0.15 for a variable to enter and remain in the model). The WCV was computed from the series of 6 measurements (2 samplings in each of Weeks 21, 22 and 23). The influence of the time of the year (1st, 2nd, 3rd and 4th quarters), calculated age at enrolment and disease condition on the IGF-I value were assessed.; Parameter estimates from the statistical model are presented as least squares means for the categories of time of the year (1st, 2nd, 3rd and 4th quarters), calculated age at enrolment and disease condition (GHD and TS).	Up to Week 24
Secondary	Change From Baseline at Week 24 in the IGF-I Levels as Measured by Capillary Blood Spot Method and Serum IGF-I Assay	3 simultaneous IGF-I measurements were taken at Weeks 0 (baseline), 12 and 24 by serum and capillary assay to determine the precision profile of the capillary blood spot method versus the serum IGF-I assay.; Change from baseline at Week 24 in the IGF-I measurements by capillary blood spot method and serum assay are presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 12 and Week 24 in Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Measurements	The LWPES recommends that treatment for any indication with recombinant GH therapy in children be accompanied by regular monitoring of IGF-I and IGFBP3 concentrations. IGFBP3 binds circulating IGF-I and serum samples were taken at Visit 1 (Week 0), Visit 2 (Week 12) and Visit 3 (Week 24) in order to measure IGFBP3.; Change from baseline (Visit 1) at Visits 2 and 3 in IGFBP3 is presented.	Baseline to Week 12 and Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Height	The auxological parameter, height, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).; Change from baseline in measured height at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Calculated Height SDS	The auxological parameter, height, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Height SDS = (height - reference mean height (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in growth, therefore, a favorable outcome.; Change from baseline in the calculated height SDS at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Weight	The auxological parameter, weight, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).; Change from baseline in measured weight at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Calculated Weight SDS	The auxological parameter, weight, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Weight SDS = (weight - reference mean weight (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in weight, therefore, a favorable outcome.; Change from baseline in the calculated weight SDS at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Annualised Growth Velocity	The auxological parameter, annualised growth velocity, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).; Change from baseline in the measured annualised growth velocity at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Change From Baseline at Week 24 in the Auxological Parameter Annualised Growth Velocity SDS	The auxological parameter, annualised growth velocity, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Annualised GV SDS = (annualised GV - reference mean annualised GV (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in growth velocity, therefore, a favorable outcome.; Change from baseline in the annualised growth velocity SDS at Visit 3 (Week 24) for the overall ITT population is presented.	Baseline to Week 24
Secondary	Percentage of Patients Rating the Overall Handling of the Administration Device, NutropinAq Pen, to Assess the Acceptability and Tolerance of NutropinAq and Its Pen	The acceptability was evaluated by a questionnaire at Month 5. The users (parents and/or child) of NutropinAq pen and compliance aid booklet were asked to describe and rate the pen, cartridge, compliance aid booklet and their ease of use.; The percentage of patients responding to each category for the assessment of the overall handling of the NutropinAq pen are presented. The categories are: Very easy, Easy, Moderately difficult, Difficult, Very difficult and Missing.	At Month 5
Secondary	Posology of NutropinAq at Baseline (Visit 1) Summarised as Mean Dose	It was intended that the posology (mg/kg/day) of NutropinAq would remain constant throughout the study. The mean posology adopted at Visit 1 is presented.	Visit 1 (Baseline)
Secondary	Extent of Exposure to NutropinAq Throughout the Study	The extent of treatment exposure throughout the study is presented as the mean number of daily injections performed.	Up to Week 24